Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 1
Submit an article Journal homepage
1,492
Views
3
CrossRef citations to date
0
Altmetric
Reviews

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe

E VrdoljakUniversity Hospital Split, Department of Oncology, Split, CroatiaCorrespondence[email protected]
,
L TordayUniversity of Szeged, Department of Oncotherapy, Szeged, Hungary
,
C SzczylikCentral Clinical Hospital, Department of Oncology, Military Institute of Medicine, Warsaw, Poland
,
G KharkevichNN Blokhin Russian Cancer Research Center, Biotherapy Department, Moscow, Russia
,
S BavbekVKV American Hospital, Div. Medical Oncology, Istanbul, Turkey
&
A SellaAssaf Harofeh Centre Zerifin, Department of Oncology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Pages 93-104 | Published online: 30 Nov 2015

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

C. Vargas, C. Balmaceda, F. Rodríguez, R. Rojas, A. Giglio & M. A. Espinoza. (2019) Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison. Expert Review of Pharmacoeconomics & Outcomes Research 19:5, pages 609-617.
Read now
Sebastiano Buti, Alessandro Leonetti, Alice Dallatomasina & Melissa Bersanelli. (2016) Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evidence 11, pages 23-36.
Read now

Articles from other publishers (1)

Yoshiko Umeyama, Yoshiyuki Shibasaki & Hideyuki Akaza. (2017) Axitinib in metastatic renal cell carcinoma: beyond the second-line setting. Future Oncology 13:21, pages 1839-1852.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.